Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
- DOI
- 10.1007/s40256-021-00491-9
- Published
- 2022 Jan
- Container
- American journal of cardiovascular drugs : drugs, devices, and other interventions
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40256-021-00491-9,
title = {Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.},
author = {Jensen IS and Wu E and Cyr PL and Claussen M and Winkler T and Salahuddin K and Prats J and Mahaffey KW and Gibson CM and Steg PG and Stone GW and Bhatt DL},
year = {2022},
journal = {American journal of cardiovascular drugs : drugs, devices, and other interventions},
doi = {10.1007/s40256-021-00491-9},
url = {https://doi.org/10.1007/s40256-021-00491-9}
}RIS
TY - JOUR TI - Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. AU - Jensen IS AU - Wu E AU - Cyr PL AU - Claussen M AU - Winkler T AU - Salahuddin K AU - Prats J AU - Mahaffey KW AU - Gibson CM AU - Steg PG AU - Stone GW AU - Bhatt DL PY - 2022 JO - American journal of cardiovascular drugs : drugs, devices, and other interventions DO - 10.1007/s40256-021-00491-9 UR - https://doi.org/10.1007/s40256-021-00491-9 ER -
APA
IS, J., E, W., PL, C., M, C., T, W., K, S., J, P., KW, M., CM, G., PG, S., GW, S., & DL, B. (2022). Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.. American journal of cardiovascular drugs : drugs, devices, and other interventions. https://doi.org/10.1007/s40256-021-00491-9
Source records
- pubmed · retrieved 2026-09-25T17:40:25.182Z